SMN2 and proximal spinal muscular atrophy: This platform can be used to develop target-selective small molecules, such as the first-ever orally bioavailable modifier of survival of motor neuron 2 (SMN2) splicing for the treatment of spinal muscular atrophy (SMA)9.